Skip to main content

Table 1 Data sources for base case and sensitivity analyses

From: Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective

Inputs

Base case

Sensitivity analysis

Risk of developing CHF

Based on risk scores and the standard model risk equations developed by Chow et al. [13]

Based on the Hazard ratio for CHF in a cohort of adult survivors of childhood and adolescent cancer according to anthracycline dose [16]

Extrapolation of cumulative CHF incidence

Polynomial

Linear

Risk of dying from non-CHF causes

Based on cause-specific cumulative mortality curves developed by Mertens et al. [20]

Based on life tables combined with SMR [21]

Treatment effect calculations

Based on meta-analysis of data from non-randomized and randomized studies using M–H approach

Based on Bayesian meta-analysis of data from non-randomized and randomized studies

Utility values

As presented in Wong et al. [22]

Based on New York Heart Association classes I and III, [0.855 (0.845; 0.846) and 0.673 (0.665; 0.690)] representing heath states ALVD and CHF respectively

[23]

  1. ALVD asymptomatic left ventricular dysfunction, CHF congestive heart failure, SMR standardised mortality ratio